4.7 Review

How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 10, 页码 1276-1289

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.735

关键词

disability; disparities; heart failure; hospice; left ventricular assist device; palliative care

资金

  1. American Heart Association
  2. AstraZeneca
  3. Luitpold
  4. Novartis
  5. Merck
  6. National Heart, Lung, and Blood Institute
  7. Patient Centered Outcomes Research Institute
  8. Janssen
  9. St. Jude
  10. ZS Pharma
  11. National Institutes of Health

向作者/读者索取更多资源

Advances in medicine have changed how patients experience the end of life. With longer life spans, there has also been an increase in years lived with disability. The clustering of illnesses in the last years of life is particularly pronounced in patients with cardiovascular disease. At the end of life, patients with cardiovascular disease are more symptomatic, less likely to die at home, and less likely to receive high-quality palliative care. Social determinants have created widening disparities in end-of-life care. The increasing complexity and duration of care have resulted in an epidemic of caregiver burden. Modern medical care has also resulted in new ethical challenges, for example, those related to deactivation of cardiac devices, such as pacemakers, defibrillators, and mechanical circulatory support. Recommendations to improve end-of-life care for patients with cardiovascular disease include optimizing metrics to assess quality, ameliorating disparities, enhancing education and research in palliative care, overcoming disparities, and innovating palliative care delivery and reimbursement. (J Am Coll Cardiol 2017;70:1276-89) (C) 2017 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据